Tideglusib - AMO Pharma
Alternative Names: AMO-02; NP-031112; NP-12; Nypta; ZentylorLatest Information Update: 06 May 2024
At a glance
- Originator Neuropharma
- Developer AMO Pharma; Brock University; Noscira
- Class Anti-inflammatories; Antidementias; Behavioural disorder therapies; Naphthalenes; Neuroprotectants; Small molecules; Thiadiazoles
- Mechanism of Action Glycogen synthase kinase 3 beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Myotonic dystrophy
- Preclinical Duchenne muscular dystrophy
- No development reported Autistic disorder
- Discontinued Alzheimer's disease; Progressive supranuclear palsy
Most Recent Events
- 02 May 2024 AMO Pharma completes meeting with US FDA for advancement of AMO 02 for Type 1 myotonic dystrophy
- 02 May 2024 AMO Pharma announces intention to submit NDA to regulatory body for myotonic dystrophy (In children, In adolescents, In adults)
- 02 May 2024 AMO Pharma plans a phase III trial for Type 1 myotonic dystrophy (In adults)